Cargando…

The miR‐200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR‐3 and MES‐OV cells

We studied the role of miRNA‐200 family members in cellular sensitivity to paclitaxel and carboplatin, using two ovarian cancer cell lines, OVCAR‐3 and MES‐OV, and their paclitaxel resistant variants OVCAR‐3/TP and MES‐OV/TP. Both resistant variants display a strong epithelial‐mesenchymal transition...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brozovic, Anamaria, Duran, George E., Wang, Yan C., Francisco, E. Brian, Sikic, Branimir I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788969/ https://www.ncbi.nlm.nih.gov/pubmed/26025631 http://dx.doi.org/10.1016/j.molonc.2015.04.015

Ejemplares similares

Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines
por: Tilli, Tatiana M, et al.
Publicado: (2014)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

Synergistic Effect of COX-2 Inhibitor on Paclitaxel-Induced Apoptosis in the Human Ovarian Cancer Cell Line OVCAR-3
por: Kim, Hee Jung, et al.
Publicado: (2014)

MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells
por: Chen, G K, et al.
Publicado: (2000)

Temperature‐sensitive Ovarian Carcinoma Cell Line (OvBH‐1)
por: Bar, Julia K., et al.
Publicado: (2002)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Overexpression of miR-148a inhibits viability and invasion of ovarian cancer OVCAR3 cells by targeting FOXO3
por: Zhu, Dandan, et al.
Publicado: (2019)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

Endoplasmic Reticulum Stress Is Involved in the Response of Human Laryngeal Carcinoma Cells to Carboplatin but Is Absent in Carboplatin-Resistant Cells
por: Brozovic, Anamaria, et al.
Publicado: (2013)

Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro
por: Uruski, Paweł, et al.
Publicado: (2021)

Antitumor Effects of Turmeric on OVCAR-3 Ovarian Cancer Cell Lines
por: Gurer, Hulusi Goktug, et al.
Publicado: (2022)

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
por: Weng, Chia-Sui, et al.
Publicado: (2019)

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
por: Wagner, U, et al.
Publicado: (2012)

miR-940 Upregulation Suppresses Cell Proliferation and Induces Apoptosis by Targeting PKC-δ in Ovarian Cancer OVCAR3 Cells
por: Wang, Fang, et al.
Publicado: (2017)

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
por: Rob, Lukas, et al.
Publicado: (2022)

Catalpol Suppresses Proliferation and Facilitates Apoptosis of OVCAR-3 Ovarian Cancer Cells through Upregulating MicroRNA-200 and Downregulating MMP-2 Expression
por: Gao, Na, et al.
Publicado: (2014)

Transcriptome profile of OVCAR3 cisplatin-resistant ovarian cancer cell line
por: Sakhare, Shruti S, et al.
Publicado: (2014)

" Mes découvertes ont dépassé mes attentes"
por: Rey, P
Publicado: (1999)

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
por: Siddiqui, N., et al.
Publicado: (1997)

The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer
por: Dermitzakis, Emmanouil V., et al.
Publicado: (2016)

miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases
por: Liu, Jue, et al.
Publicado: (2019)

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
por: Gao, Bo, et al.
Publicado: (2018)

The miR-200 family in ovarian cancer
por: Koutsaki, Maria, et al.
Publicado: (2017)

Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer
por: Lee, C K, et al.
Publicado: (2011)

Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene
por: Ntemou, E., et al.
Publicado: (2022)

Tandem Use of OvMANE1 and Ov-16 ELISA Tests Increases the Sensitivity for the Diagnosis of Human Onchocerciasis
por: Shintouo, Cabirou Mounchili, et al.
Publicado: (2021)

The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance
por: Duran, George E., et al.
Publicado: (2019)

MiR-124-3p.1 Sensitizes Ovarian Cancer Cells to Mitochondrial Apoptosis Induced by Carboplatin
por: Deng, Xiaohong, et al.
Publicado: (2020)

Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan
por: Harano, Kenichi, et al.
Publicado: (2014)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
por: Tate, Shinichi, et al.
Publicado: (2021)

La apicultura mes a mes : cómo cuidar el colmenar de enero a diciembre /
por: Riondet, Jean
Publicado: (2022)

Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition
por: Duran, George E, et al.
Publicado: (2017)

Effects of sequential paclitaxel–carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study
por: Wang, Fei, et al.
Publicado: (2016)

Ischemic Colitis Associated with Paclitaxel and Carboplatin Combination
por: Elsayed, Ahmed Gamal, et al.
Publicado: (2017)

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
por: Mullany, Sally, et al.
Publicado: (2020)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer
por: Meng, Xiaodan, et al.
Publicado: (2016)

Galectin-9 induces apoptosis in OVCAR-3 ovarian cancer cell through mitochondrial pathway
por: Jafari, Seyyed Mehdi, et al.
Publicado: (2018)

Synergistic Effect of Saccharin and Caffeine on Antiproliferative Activity in Human Ovarian Carcinoma Ovcar-3 Cells
por: Lee, Sun Ju, et al.
Publicado: (2023)

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer
por: Guppy, A E, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_2ca9v94o8qhahb9smmkr4tekco